1. Generics Bulletin
  2. >>Products
  3. >>Generics

Hikma Plans to Partner Away From Branded Generics Focus In MENA

 
• By Aidan Fry

With local competitors in the MENA region increasingly able to compete on branded generics, Jordan’s Hikma is shifting the focus of its local operation towards partnering for patent-protected products.

Middle East
Hikma is shifting its focus in the MENA region away from branded generics and towards patent-protected brands • Source: Shutterstock

Hikma is positioning itself as the ‘partner of choice’ for firms looking to broaden distribution of their patent-protected products in the Middle East and Africa (MENA) region. Increased competition from local players is encouraging the Jordanian company to shift away from its historical strength in branded generics.

Addressing investors, chief executive officer Siggi Olafsson said the MENA trading environment was changing. “A few years back, there wasn't so much price erosion in the market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.